<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143508" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Meibomian Gland Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaur</surname>
            <given-names>Kirandeep</given-names>
          </name>
          <aff>Aravind Eye Hospital, Pondicherry</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stokkermans</surname>
            <given-names>Thomas J.</given-names>
          </name>
          <aff>University Hospitals of Cleveland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kirandeep Kaur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Stokkermans declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143508.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Meibomian gland dysfunction encompasses various disorders affecting the meibomian glands, causing ocular discomfort, dry eyes, and visual disturbances. Factors like aging, digital device use, and hormonal changes contribute to its onset. Blocked meibomian ducts lead to reduced lipid secretion, tear film instability, and ocular surface inflammation. Diagnosis relies on outpatient tests and questionnaires to determine disease severity, guiding treatment decisions.</p>
        <p>Clinicians participating in this activity&#x000a0;can expect to gain comprehensive insights into the condition, including its diverse etiology, pathophysiology, evaluation, and management strategies. Clinicians enhance their ability to recognize and diagnose meibomian gland dysfunction promptly, allowing for early intervention and improved patient outcomes. Specifically, they learn to identify risk factors associated with meibomian gland dysfunction, understand the impact of blocked meibomian ducts on tear film stability, and interpret key clinical indicators of disease severity.&#x000a0;Moreover, clinicians become proficient in utilizing outpatient tests and patient questionnaires to guide treatment decisions tailored to patients' needs. Ultimately, participation in this&#x000a0;activity empowers healthcare professionals with the knowledge and skills to manage meibomian gland dysfunction effectively, thereby enhancing the quality of care provided to patients suffering from this common ocular condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical manifestations of meibomian gland disease during patient examinations.</p></list-item><list-item><p>Screen patients for meibomian gland disease using appropriate diagnostic tools and assessments.</p></list-item><list-item><p>Implement evidence-based treatment plans for managing meibomian gland disease in clinical practice.</p></list-item><list-item><p>Collaborate with other healthcare professionals to optimize comprehensive care for patients with meibomian gland disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143508&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143508">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-143508.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Meibomian gland disease encompasses a range of meibomian gland disorders, including meibomian gland dysfunction (MGD), neoplasia, and congenital disease.&#x000a0;MGD refers to the abnormalities in the function of the meibomian glands. The International Workshop on&#x000a0;MGD describes MGD&#x000a0;as a "chronic diffuse abnormality of the meibomian glands, characterized by terminal duct obstruction along with qualitative or quantitative changes in the glandular secretion."<xref ref-type="bibr" rid="article-143508.r1">[1]</xref>&#x000a0;</p>
        <p>Dysfunction in meibomian gland secretion can adversely influence the amount and quality of secreted meibum, leading to alterations in tear film composition and compromising ocular surface health.&#x000a0;This can result in&#x000a0;tear film abnormalities, ocular surface inflammation or irritation, or ocular surface disease.<xref ref-type="bibr" rid="article-143508.r2">[2]</xref>&#x000a0;&#x000a0;</p>
        <p>Named after the German physician and anatomist Heinrich Meibom, the meibomian glands are sebaceous glands in the eyelid.<xref ref-type="bibr" rid="article-143508.r3">[3]</xref>&#x000a0;The upper lid contains approximately 20 to 30 meibomian glands, and the lower lid has 40 to 50.<xref ref-type="bibr" rid="article-143508.r4">[4]</xref>&#x000a0;These glands lie parallel in a single row within the tarsal plates of the upper and lower lids, with the proximal ends of the meibomian glands extending toward the proximal margin of the tarsal plates. The distal end of the tarsus receives meibum through the excretory duct into the lid margin.&#x000a0;</p>
        <p>Meibum, composed primarily of lipids, stabilizes the tear film by lowering the surface tension, acts as a lubricant during blinking, prevents excessive evaporation of the tear film's aqueous layer, and provides an outer barrier that prevents bacteria from entering the tear film.<xref ref-type="bibr" rid="article-143508.r5">[5]</xref>&#x000a0;MGD is considered acute or chronic based on the duration of symptoms. Secretion rates of the glands determine further categorization. Low delivery states, or meibomian sicca, are due to gland hyposecretion or cicatricial or noncicatricial obstruction.<xref ref-type="bibr" rid="article-143508.r6">[6]</xref>&#x000a0;</p>
        <p>High delivery states, or meibomian seborrhea, involve gland hypersecretion, as noted in patients with acne rosacea or seborrheic dermatitis.<xref ref-type="bibr" rid="article-143508.r7">[7]</xref>&#x000a0;These states are then further divided into primary and secondary causes.&#x000a0;</p>
      </sec>
      <sec id="article-143508.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The most common type of MGD is the obstructive form, resulting from obstruction of the meibomian gland terminal duct. Obstruction occurs due to ductal epithelium hypertrophy, keratinization, and the viscous nature of meibum. The result is atrophy and dropout of the meibomian glands, thus decreasing secretion.</p>
        <p>Meibomian gland atrophy and medication effects cause meibomian sicca. Atrophy of meibomian glands results in an overall reduction in functional meibomian glands. The underlying risk factors that can lead to MGD are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age</p>
          </list-item>
          <list-item>
            <p>Androgen deficiency</p>
          </list-item>
          <list-item>
            <p>History of atopy</p>
          </list-item>
          <list-item>
            <p>Sjogren syndrome</p>
          </list-item>
          <list-item>
            <p>Steven-Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Acne rosacea</p>
          </list-item>
          <list-item>
            <p>Contact lenses</p>
          </list-item>
          <list-item>
            <p>Eyelid tattooing</p>
          </list-item>
          <list-item>
            <p>Systemic antibiotic use</p>
          </list-item>
          <list-item>
            <p>Medications like isotretinoin for acne, antidepressants, or hormone replacement therapy</p>
          </list-item>
          <list-item>
            <p>Topical medications like epinephrine,&#x000a0;beta-blockers, prostaglandin analogs, and carbonic anhydrase inhibitors</p>
          </list-item>
          <list-item>
            <p>Chronic blepharitis</p>
          </list-item>
          <list-item>
            <p>Trachoma&#x000a0;<xref ref-type="bibr" rid="article-143508.r8">[8]</xref><xref ref-type="bibr" rid="article-143508.r9">[9]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The microbiome of the ocular surface also may play a role in MGD.&#x000a0;Infestation of the follicle of the eyelash, the sebaceous gland of Zeis, and the meibomian glands by the Demodex mite affect the functioning of the meibomian glands. Studies reveal that nearly 50% of patients with MGD also have Demodex mite infestation.<xref ref-type="bibr" rid="article-143508.r10">[10]</xref><xref ref-type="bibr" rid="article-143508.r11">[11]</xref><xref ref-type="bibr" rid="article-143508.r12">[12]</xref>&#x000a0;Causes of&#x000a0;cicatricial MGD are trachoma, erythema multiforme, and pemphigoid. Noncicatricial MGD is often associated with acne rosacea, atopic dermatitis, seborrheic dermatitis, and psoriasis.</p>
      </sec>
      <sec id="article-143508.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>MGD&#x000a0;is a globally prevalent disorder. In a meta-analysis by Hassanzadeh et al, the estimated global prevalence is 35.8%, with a higher incidence in men than women.<xref ref-type="bibr" rid="article-143508.r13">[13]</xref> Asian patients have a higher incidence of MGD and meibomian gland dropout than White patients.<xref ref-type="bibr" rid="article-143508.r13">[13]</xref></p>
        <p>Clinically, MGD presents as gland atrophy, obstruction, changes in meibum quality, and eyelid vascularity. Research by Alghamdi et al reveals that 59% of participants with MGD have at least 1 abnormal meibomian gland parameter, found most commonly in older male patients.<xref ref-type="bibr" rid="article-143508.r13">[13]</xref></p>
        <p>While the meibum quality does not differ significantly between races, White patients exhibit more frequent eyelid vascularity abnormalities. A study conducted by Badian et al involving patients with subjective dry eyes reveals a 93.8% prevalence of MGD without significant age or gender differences.<xref ref-type="bibr" rid="article-143508.r13">[13]</xref></p>
      </sec>
      <sec id="article-143508.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The classification of&#x000a0;MGD depends on meibomian gland secretion. Low-delivery states are hyposecretory or obstructive, with further subdivision into cicatricial and noncicatricial subcategories. Patients with the hyposecretory form have abnormalities in meibomian glands without obstruction, while terminal duct obstruction causes the obstructive form. In the cicatricial form, the duct orifices are dragged posteriorly into the mucosa, whereas in patients with nonscarring MGD, the duct orifices remain normal. High-delivery states represent meibomian gland hypersecretion.</p>
        <p>
<bold>Low Delivery State Meibomian Gland Dysfunction</bold>
</p>
        <p>Obstruction is the most common cause of MGD.<xref ref-type="bibr" rid="article-143508.r5">[5]</xref>&#x000a0;The underlying pathophysiology is epithelial hyperkeratinization causing duct obstruction, meibum stasis, cystic dilation, acinar atrophy due to disuse, and gland dropout. Meibocyte differentiation and renewal also play a role.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Aging:&#x000a0;</bold>Meibomian gland acinar epithelial cell atrophy and decreased lipid production occurs with aging. These changes are likely due to&#x000a0;reduced differentiation and cell renewal of meibocytes, decreased meibomian gland size, and increasing infiltration of inflammatory cells. The downregulation of peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;), a nuclear receptor protein that regulates meibocyte differentiation and lipid biosynthesis, correlates with these changes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Environmental stress:&#x000a0;</bold>Low-humidity environments cause&#x000a0;increased cellular proliferation and turnover to&#x000a0;increase meibum production. The long-term result may be ductal dilation and a decrease in the number of functioning meibocytes, causing gland atrophy and hyposecretion. Poorly functioning meibocytes lose the ability to remove protein from the meibum, altering the protein-to-lipid ratio. Meibum becomes viscous, disrupting the stability of the tear film. Like the cornea, aging and environmental stress over time cause the depletion of meibocyte stem cells.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hormonal effects: </bold>Androgens stimulate meibum secretion and suppress inflammation, while estrogens&#x000a0;tend to increase&#x000a0;inflammation. Androgen-depleted states, such as patients using antiandrogen agents, those with complete androgen insensitivity syndrome, and&#x000a0;Sj&#x000f6;gren&#x000a0;syndrome, may&#x000a0;lead to the development of MGD.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Medications:&#x000a0;</bold>Both systemic and topical medications contribute to the low-flow form of MGD. Medications like &#x003b2;-blockers and carbonic anhydrase inhibitors used for glaucoma cause&#x000a0;decreased acinar area, acinar density, and homogenous acinar wall morphology. Topical epinephrine results in hyperkeratinization of the duct epithelium, leading to meibomian gland plugging and dilation. Retinoic acid binds to nuclear receptors and changes in gene transcription. The volume of acinar tissue decreases, inhibiting the maturation of lipid-laden meibomian acinar cells.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Microbiome:&#x000a0;</bold>Cholesterol esters in the meibum stimulate the growth of some bacteria on the margin of the eyelid.&#x000a0;<italic toggle="yes">Staphylococcus epidermidis</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, and <italic toggle="yes">Propionibacterium acnes </italic>are most commonly involved. These bacteria&#x000a0;produce lipolytic enzymes and release inflammatory mediators, causing lipolysis in the tear film and loss of tear film integrity.<xref ref-type="bibr" rid="article-143508.r14">[14]</xref> The instability of the tear film causes increased evaporation of the aqueous layer and hyperosmolarity.<xref ref-type="bibr" rid="article-143508.r15">[15]</xref>&#x000a0;Changes in the tear film's flora also lead to the release of toxins, which result in eyelid inflammation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contact lens use:&#x000a0;</bold>Contact lenses result in irreversible meibomian gland dropout. The exact pathophysiology is poorly understood, but the proposed mechanisms are&#x000a0;mechanical trauma,&#x000a0;plugging due to aggregation of desquamated epithelial cells at gland orifices,&#x000a0;and chronic inflammation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Congenital:&#x000a0;</bold>Patients may be born with a decreased number of or absent meibomian glands. These changes may be present in patients with&#x000a0;Turner syndrome, ectrodactyly with ectodermal dysplasia and cleft lip and palate (ECC syndrome), and anhidrotic ectodermal dysplastic syndrome. Patients with distichiasis have an extra row of eyelashes from the meibomian glands. Congenital distichiasis can occur in isolation or as part of a syndrome.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neoplastic:&#x000a0;</bold>In addition to sebaceous gland tumors of the eyelids, chemotherapy, radiation, biological therapies, and hormonal therapies all contribute to MGD in patients with various malignancies.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>
<bold>High Delivery State Meibomian Gland Dysfunction</bold>
</bold>
</p>
        <p>The characteristic feature of the high delivery state of MGD is the release of a large lipid volume at the lid margin. Seborrheic dermatitis and acne rosacea are 2 common causes of high-delivery MGD.</p>
      </sec>
      <sec id="article-143508.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological examination by Gutgesell et al in patients with MGD reveals obstructed and dilated ducts, enlarged acini with cystic degeneration, increased inflammatory cells, and abnormal keratinization. Additional findings are squamous metaplasia and granulation tissue formation.<xref ref-type="bibr" rid="article-143508.r16">[16]</xref>&#x000a0;</p>
        <p>In another study by Obata et al, a similar examination during the autopsy on 83 patients reported changes such as cystic dilatation of ducts and acini, thickening of the basement membrane, acini atrophy, granuloma formation, and lipogranulomatous inflammation.<xref ref-type="bibr" rid="article-143508.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-143508.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients with MGD are asymptomatic, and the degree of symptoms does not directly correlate with the amount of ocular damage. Common symptomatic complaints are dry eyes, a foreign-body sensation, photophobia, eye pain, and conjunctival injection.<xref ref-type="bibr" rid="article-143508.r2">[2]</xref>&#x000a0;Other potential findings are decreased visual acuity, excessive tearing, and bulbar hyperemia. Eyelid margin telangiectasia may be visible. In normal cases, meibum is clear and easily expressed; however, patients with MGD&#x000a0;typically&#x000a0;have opaque and viscous meibum.&#x000a0;</p>
      </sec>
      <sec id="article-143508.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinicians diagnose MGD through a clinical examination. To aid in detecting asymptomatic MGD, all patients presenting for an eye examination should ideally undergo a rating of the expressibility and texture of the meibum by applying moderate pressure over the lower lid. Efron, in collaboration with CooperVision, developed a grading scale from 0 to 4 for MGD that describes the appearance of the eyelid margin&#x000a0;and meibomian gland orifices as well as the presence of tearing and bulbar conjunctival redness:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 0:&#x000a0;A pale eyelid margin,&#x000a0;meibomian gland opening visible</p>
          </list-item>
          <list-item>
            <p>Grade 1:&#x000a0;A pink margin, cloudy expression at some gland orifices</p>
          </list-item>
          <list-item>
            <p>Grade 2:&#x000a0;A red margin, milky expression at gland orifices, increased tearing</p>
          </list-item>
          <list-item>
            <p>Grade 3:&#x000a0;A red eyelid margin, yellow and continuous expression at all gland orifices (see&#x000a0;<bold>Image.&#x000a0;</bold>Lower Eyelid Frothing)</p>
          </list-item>
          <list-item>
            <p>Grade 4: A red eyelid margin, thick yellow and continuous expression at all gland orifices, and bulbar conjunctival redness&#x000a0;<xref ref-type="bibr" rid="article-143508.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>A symptom questionnaire is helpful for symptomatic patients&#x000a0;in quantitatively&#x000a0;measuring symptoms resulting from MGD. Paugh et al developed a specific questionnaire using psychometric approaches among noncontact lens wearers.<xref ref-type="bibr" rid="article-143508.r19">[19]</xref>&#x000a0;Additional symptom assessment questionnaires include the Ocular Surface Disease Index (OSDI) and the Dry Eye Questionnaire (DEQ).<xref ref-type="bibr" rid="article-143508.r20">[20]</xref>&#x000a0;Following questionnaire administration, symptomatic patients should undergo a slit-lamp examination, including the following based on availability:</p>
        <list list-type="bullet">
          <list-item>
            <p>Evaluation of lid morphology:&#x000a0;Meibography using either a transillumination technique, in which the clinician everts the eyelid over a light source or an infrared video camera, to look for lid margin irregularities, pouting or plugging of the orifices, vascular engorgement, and changes in the mucocutaneous junction.<xref ref-type="bibr" rid="article-143508.r21">[21]</xref>&#x000a0;Note any evidence of eyelid thickening, dimpling, notching, pitting, tenderness, ridge formation between the meibomian glands, or distichiasis.<xref ref-type="bibr" rid="article-143508.r22">[22]</xref>&#x000a0;Meibography was first described by&#x000a0;Tapie in 1977,&#x000a0;using UV Wood's light to fluoresce the meibomian ducts on biomicroscopy and infrared light to illuminate the meibomian glands.<xref ref-type="bibr" rid="article-143508.r23">[23]</xref>&#x000a0;This imaging technique is helpful for direct in vivo visualization of the morphology of meibomian glands (see <bold>Image.&#x000a0;</bold>MGD on Meibography). Meibography methods have evolved to include infrared meibography, visible light transillumination, laser confocal meibography, and optical coherence tomographic meibography. An example of one such system is the LipiView analyzer (Johnson and Johnson), which uses interferometry or specular reflection and allows high-resolution images of the lipid layer.<xref ref-type="bibr" rid="article-143508.r24">[24]</xref>&#x000a0;The average lipid layer thickness is 60 nm. A thin lipid layer is characteristic in patients with MGD and often corresponds to symptoms. Results of meibography are measured using the meiboscore, meibograde method, and Pult scale. The meiboscore for each eye's upper and lower lids is calculated separately and graded from 0 to 3; thus, a total score out of 6 is given for each eye.<xref ref-type="bibr" rid="article-143508.r25">[25]</xref>&#x000a0;The scoring is based on the following points:
<list list-type="bullet"><list-item><p>The lid has partial or missing glands</p></list-item><list-item><p>The affected lid area is &#x0003c;33%</p></list-item><list-item><p>The affected lid area is 33% to 66%</p></list-item><list-item><p>The affected lid area is &#x0003e;66%</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Expressibility from the meibomian gland openings:&#x000a0;Meiobiam gland openings should be patent with the expression of clear fluid.<xref ref-type="bibr" rid="article-143508.r26">[26]</xref>&#x000a0;Note the number of functional glands, obstructive capping or plugging, and the color and consistency of the meibum. Transillumination through everted eyelids or infrared photography detects meibomian gland dropout.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Calculate the blink rate and note the pattern of blinks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tear film volume:&#x000a0;The tear meniscus should be &#x0003e;10 mm&#x000a0;<xref ref-type="bibr" rid="article-143508.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tear osmolarity:&#x000a0;Hyperosmolar tears are irritative to the ocular surface.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tear film break-up time:&#x000a0;Fluorescein stain in the eye measures tear film stability. Patients are asked not to blink, and a slit-lamp visualizes the tear film. The green tear film should initially appear smooth. The patient's tear film is abnormal if blue gaps develop in less than 10 seconds. The tear film break-up time (TFBUT) of 15 to 45 seconds is normal, 10 to 15 seconds is borderline, and less than 10 seconds is abnormal.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Schirmer test:&#x000a0;This test quantifies the number of tears produced by each eye using Whatman number 41 strips, measuring 5 mm wide and 35 m long. Results are measured as the millimeters of tears collected over 5 minutes. Despite&#x000a0;its&#x000a0;common usage, this test&#x000a0;yields variable results. Normal values&#x000a0;typically range around 15 mm, while 5 to 10 mm is considered borderline, and &#x0003c;5 mm&#x000a0;is&#x000a0;classified as abnormal.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Conjunctival and corneal staining:&#x000a0;Fluorescein staining&#x000a0;is utilized to assess&#x000a0;the continuity in the corneal surface. Lissamine green or Rose Bengal staining highlights the dead and devitalized epithelium in the cornea.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The Fluorescein clearance test:&#x000a0;Detect residual fluorescein 15 minutes after instilling a drop of 2% fluorescein in the culdesac.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Interferometry:&#x000a0;Infererometry assesses the tear film lipid layer.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mass spectrometry:&#x000a0;Looks for the presence of inflammatory cell markers and provides information regarding the overall ocular surface inflammatory status.&#x000a0;</p>
          </list-item>
        </list>
        <p>Positive results on the patient symptom questionnaire, measurement of tear osmolarity, TFBUT, and conjunctival and corneal staining provide evidence of dry eye disease (see <bold>Image.&#x000a0;</bold>MGD Induced Dry Eye Sequelae). To differentiate between evaporative dry eye disease and low flow MGD,&#x000a0;measuring&#x000a0;tear flow, tear meniscus height, or performing a Schirmer test is necessary. If the diagnosis of MGD remains unclear, quantifying morphologic lid features, meibum expressibility, and quality and conducting meibography to quantify gland dropout is essential.</p>
        <p>Various&#x000a0;imaging devices are available to evaluate the meibomian glands, many combining meibomian gland imaging with an ocular surface and adnexa evaluation. One such device combines infrared meibography with noninvasive TFBUT measurement, tear meniscus height assessment, interferometry, and conjunctival redness evaluation. Another device combines infrared and visible light transillumination imaging of the meibomian glands combined with interferometry and analysis of blink dynamics, including the number of incomplete blinks.<xref ref-type="bibr" rid="article-143508.r28">[28]</xref></p>
        <p>MGD staging is&#x000a0;based on symptoms, expressibility and secretion from the meibomian glands, and corneal staining (see&#x000a0;<bold>Table 1.&#x000a0;</bold>Staging of Meibomian Gland Dysfunction).<xref ref-type="bibr" rid="article-143508.r4">[4]</xref></p>
        <table-wrap id="article-143508.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1.&#x000a0;Staging of Meibomian Gland Dysfunction</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr>
                <td style="width: 63.65625px;" rowspan="1" colspan="1">
<bold>Stage</bold>
</td>
                <td style="width: 279.453125px;" rowspan="1" colspan="1">
<bold>Symptoms</bold>
</td>
                <td style="width: 146.75px;" rowspan="1" colspan="1">
<bold>Meibomian Gland Secretions</bold>
</td>
                <td style="width: 126.1875px;" rowspan="1" colspan="1">
<bold>Corneal staining</bold>
</td>
              </tr>
              <tr>
                <td style="width: 63.65625px;" rowspan="1" colspan="1">
<bold>1</bold>
</td>
                <td style="width: 279.453125px;" rowspan="1" colspan="1">None</td>
                <td style="width: 146.75px;" rowspan="1" colspan="1">Minimally altered expressibility and secretion quality</td>
                <td style="width: 126.1875px;" rowspan="1" colspan="1">None</td>
              </tr>
              <tr>
                <td style="width: 63.65625px;" rowspan="1" colspan="1">
<bold>2</bold>
</td>
                <td style="width: 279.453125px;" rowspan="1" colspan="1">Mild</td>
                <td style="width: 146.75px;" rowspan="1" colspan="1">Mildly altered expressibility and secretion quality</td>
                <td style="width: 126.1875px;" rowspan="1" colspan="1">None to limited to the periphery</td>
              </tr>
              <tr>
                <td style="width: 63.65625px;" rowspan="1" colspan="1">
<bold>3</bold>
</td>
                <td style="width: 279.453125px;" rowspan="1" colspan="1">Moderate</td>
                <td style="width: 146.75px;" rowspan="1" colspan="1">Moderately altered expressibility and secretion quality</td>
                <td style="width: 126.1875px;" rowspan="1" colspan="1">Moderate, mainly peripheral</td>
              </tr>
              <tr>
                <td style="width: 63.65625px;" rowspan="1" colspan="1">
<bold>4</bold>
</td>
                <td style="width: 279.453125px;" rowspan="1" colspan="1">Marked</td>
                <td style="width: 146.75px;" rowspan="1" colspan="1">Severely altered expressibility and secretion quality</td>
                <td style="width: 126.1875px;" rowspan="1" colspan="1">Marked, reaches the central area</td>
              </tr>
              <tr>
                <td style="width: 63.65625px;" rowspan="1" colspan="1">
<bold>Plus disease</bold>
</td>
                <td style="width: 279.453125px;" rowspan="1" colspan="1">Coexisting disorders of the ocular surface or eyelids</td>
                <td style="width: 146.75px;" rowspan="1" colspan="1">&#x000a0;-</td>
                <td style="width: 126.1875px;" rowspan="1" colspan="1">&#x000a0;-</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Several studies, including the&#x000a0;Dry Eye Assessment and Management (DREAM) study, attempted to interpret meibography images by categorizing morphological features of meibomian glands.<xref ref-type="bibr" rid="article-143508.r29">[29]</xref>&#x000a0; Earlier studies identified meibomian gland tortuosity as an indication of MGD and upper eyelid&#x000a0;meibomian gland&#x000a0;tortuosity as a predictor of contact lens dropout.<xref ref-type="bibr" rid="article-143508.r30">[30]</xref>&#x000a0;&#x000a0;</p>
        <p>Halleran et al developed a scale for&#x000a0;meibomian gland&#x000a0;tortuosity:<xref ref-type="bibr" rid="article-143508.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>0:</bold> no tortuous MGs</p>
          </list-item>
          <list-item>
            <p><bold>1:</bold> &#x0003c;25% tortuous MGs</p>
          </list-item>
          <list-item>
            <p><bold>2:</bold> 26% to 50% tortuous MGs</p>
          </list-item>
          <list-item>
            <p><bold>3:</bold> 51% to 75% tortuous MGs</p>
          </list-item>
          <list-item>
            <p><bold>4:</bold> &#x0003e;75% tortuous MGs</p>
          </list-item>
        </list>
        <p>Investigators in the DREAM study identified&#x000a0;11 additional morphological features in addition to shortening and tortuosity.<xref ref-type="bibr" rid="article-143508.r29">[29]</xref>&#x000a0;These features were then assigned a severity score on a scale from 0 to 10, with 0 being the lowest severity and 10 the highest:</p>
        <list list-type="bullet">
          <list-item>
            <p>Shortening (10.0)</p>
          </list-item>
          <list-item>
            <p>Tortuosity (2.67)</p>
          </list-item>
          <list-item>
            <p>Distorted (0.67)</p>
          </list-item>
          <list-item>
            <p>Hooked (4.00)</p>
          </list-item>
          <list-item>
            <p>Drop out (10.0)</p>
          </list-item>
          <list-item>
            <p>Thickened (4.67)</p>
          </list-item>
          <list-item>
            <p>Thinned (4.33)</p>
          </list-item>
          <list-item>
            <p>Overlapping (2.67)</p>
          </list-item>
          <list-item>
            <p>Ghost (8.0)</p>
          </list-item>
          <list-item>
            <p>Tadpoling (3.67)</p>
          </list-item>
          <list-item>
            <p>Abnormal gap (3.67)</p>
          </list-item>
          <list-item>
            <p>Fluffy areas (5.67)</p>
          </list-item>
          <list-item>
            <p>No extension to the lid margin (5.0)</p>
          </list-item>
        </list>
        <p>Establishing a&#x000a0;correlation between these scales and dry eye parameters is an active field of investigation.<xref ref-type="bibr" rid="article-143508.r31">[31]</xref><xref ref-type="bibr" rid="article-143508.r32">[32]</xref>&#x000a0;This is crucial for refining diagnostic and treatment approaches for meibomian gland dysfunction.</p>
      </sec>
      <sec id="article-143508.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for MGD is defined based on the signs and symptoms. The International Workshop on&#x000a0;MGD describes treatment based on the stage of the disease.<xref ref-type="bibr" rid="article-143508.r33">[33]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1&#x000a0;
<list list-type="bullet"><list-item><p>Patients should optimize their work and home environment and avoid excessive screen time and direct exposure to wind,&#x000a0;as these factors can increase&#x000a0;the tear film evaporation rate.<xref ref-type="bibr" rid="article-143508.r34">[34]</xref>&#x000a0; Regular eyelid compresses with warm water for a minimum of 4 minutes, once or twice daily, followed by a firm massage to express inspissated secretions, is a beneficial treatment. Additionally, increasing dietary omega-3 fatty acid consumption is recommended.<xref ref-type="bibr" rid="article-143508.r35">[35]</xref><xref ref-type="bibr" rid="article-143508.r36">[36]</xref>&#x000a0;</p></list-item><list-item><p>Artificial lubricants, topical antibiotics like azithromycin, and emollient or liposomal spray may be considered case-to-case. The topical 1.0% ophthalmic solution of azithromycin is a broad-spectrum, macrolide antibiotic with anti-inflammatory properties. Oil emulsion tear substitutes improve the lipid layer thickness and overall tear film stability.<xref ref-type="bibr" rid="article-143508.r37">[37]</xref>&#x000a0;Oral tetracyclines have also demonstrated clinical improvement due to their anti-inflammatory effects.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stage 2&#x000a0;
<list list-type="bullet"><list-item><p>Patient education is essential at each stage, emphasizing the&#x000a0;influence of diet, home, or work environment on tear evaporation. Encouraging frequent blinking, particularly during activities like reading or computer use, is recommended. Additionally, discuss strategies for minimizing exposure to air conditioning or heating while suggesting using humidifiers in the bedroom or any space where the patient spends much time.</p></list-item><list-item><p>Evaluate the influence of medications taken for other systemic conditions. In this stage, warm compresses and lid expression are generally effective. Warm compresses directly heat the lid margins, melting altered meibomian secretions and providing symptomatic relief with regular treatment adherence.<xref ref-type="bibr" rid="article-143508.r33">[33]</xref></p></list-item><list-item><p>After warm compresses, digital massage of the lids facilitates the expression of thicker meibum from the glands. This manual expression clears meibomian gland duct blockages, enabling the glands to produce normal secretions. Encourage patients to maintain regular lid hygiene through warm water lid scrubs, with or without local shampoo application.<xref ref-type="bibr" rid="article-143508.r33">[33]</xref>&#x000a0;Emphasize cleaning the base of the eyelashes behind the lid margin to reduce bacterial load and clear meibum, thereby minimizing inflammation.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stage 3&#x000a0;
<list list-type="bullet"><list-item><p>In addition to the treatments mentioned above, topical anti-inflammatory medications should be considered for treatment at this stage.<xref ref-type="bibr" rid="article-143508.r38">[38]</xref><xref ref-type="bibr" rid="article-143508.r39">[39]</xref>&#x000a0;Lubricant eye ointment at bedtime provides symptomatic relief.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stage 4&#x000a0;
<list list-type="bullet"><list-item><p>The addition of additional anti-inflammatory medications is necessary in stage 4. Topical anti-inflammatory eye drops like 0.05% cyclosporine A, topical&#x000a0;<italic toggle="yes">N</italic>-acetylcysteine, lifitegrast 5%, and topical steroids like loteprednol etabonate have shown to be beneficial in reducing inflammation in stage 4 MGD.<xref ref-type="bibr" rid="article-143508.r39">[39]</xref>&#x000a0;A selective nicotinic acetylcholine receptor agonist, varenicline, stimulates the trigeminal parasympathetic pathway in the nasal mucosa, leading to goblet cell degranulation and stimulation of meibomian gland and lacrimal gland secretions. This promotes all 3 layers of the tear film, including meibum production.<xref ref-type="bibr" rid="article-143508.r40">[40]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>In some patients with severe MGD, when conservative management is ineffective, mechanical opening of the terminal ducts and meibum expression may be necessary. Probing or electronic heating devices&#x000a0;facilitate the mechanical opening of blocked ducts or assist in meibum expression by applying heat.</p>
        <p>
<bold>Intraductal Probing</bold>
</p>
        <p>Intraductal probing is a slit lamp procedure involving the mechanical opening and dilatation of the blocked meibomian gland orifices and ducts.<xref ref-type="bibr" rid="article-143508.r41">[41]</xref>&#x000a0;Initially, 1 to 2 mm Maskin probes penetrate the gland orifices, followed by 4 to 6 mm probes to achieve ductal patency. Probing helps by releasing the meibum, opening the blocked ducts, and improving the effectiveness of topical medications. The treatment improves TFBUT, meibum lipid levels, viscosity, lid margin abnormalities, conjunctival hyperemia, and overall patient symptoms.<xref ref-type="bibr" rid="article-143508.r42">[42]</xref>&#x000a0;</p>
        <p>Syed and Sutula describe a modified technique of probing done against resistance that is beneficial in a subset of patients.<xref ref-type="bibr" rid="article-143508.r43">[43]</xref>&#x000a0;This method involves holding the lid with forceps and pulling in a direction opposite the movement of the probe.</p>
        <p>
<bold>Electronic Heating Devices</bold>
</p>
        <p>Heat helps by locally raising the temperature of the eyelids, melting the inspissated meibum.<xref ref-type="bibr" rid="article-143508.r6">[6]</xref>&#x000a0;In MGD, the altered meibomian composition leads to an increased melting point. Increased eyelid temperatures decrease the meibomian lipid viscosity while increasing the lipid levels of the tear film.</p>
        <p>Several electronic heating devices are now available on the market, with LipiFlow (Johnson and Johnson)&#x000a0;being&#x000a0;widely used and effective. This device delivers heat simultaneously to the palpebral conjunctiva of both upper and lower lids. Concurrently, it also helps express meibomian gland content by providing pressure to the outer eyelid surfaces in a pulsatile manner. Interferometry studies reveal improved meibomian gland secretion, TFBUT, and increased lipid layer thickness.<xref ref-type="bibr" rid="article-143508.r44">[44]</xref>&#x000a0;Furthermore, decreased bulbar congestion and symptomatic relief have been reported.<xref ref-type="bibr" rid="article-143508.r45">[45]</xref><xref ref-type="bibr" rid="article-143508.r46">[46]</xref>&#x000a0;However, patients must have at least 6 open meibomian glands in the lower lid to achieve effectiveness.<xref ref-type="bibr" rid="article-143508.r4">[4]</xref>&#x000a0;</p>
        <p>The Systane iLux and Systane iLux MGD Thermal Pulsation Systems (Alcon) are handheld devices&#x000a0;that enable&#x000a0;the operator to visualize the expression of the meibum while applying heat and pressure to the meibomian glands. This system has demonstrated efficacy comparable to that of LipiFlow.<xref ref-type="bibr" rid="article-143508.r47">[47]</xref></p>
        <p>The MiBo Thermoflow (MIBO), another electronic heating device model,&#x000a0;utilizes an external paddle heated to 42.2 &#x000b0;C and is applied with a gel buffer to the eyelids.<xref ref-type="bibr" rid="article-143508.r48">[48]</xref>&#x000a0;This method effectively targets the meibomian glands, aiding the liquefaction of obstructed meibum and promoting tear film stability.</p>
        <p>
<bold>Intense Pulse Laser Therapy</bold>
</p>
        <p>Intense pulse laser therapy uses a light source that generates wavelengths from 500 to 1200 nm.<xref ref-type="bibr" rid="article-143508.r49">[49]</xref>&#x000a0;When applied through the skin, these waves are absorbed by the blood vessels near the skin's surface, leading to local heat generation and coagulation, causing vessel thrombosis.<xref ref-type="bibr" rid="article-143508.r50">[50]</xref>&#x000a0;As a result, patients experience decreased redness due to abnormal telangiectatic vessels and bacteria elimination from the treated area.</p>
        <p>
<bold>Intranasal Tear Neurostimulation</bold>
</p>
        <p>Neurostimulation utilizes neural pathways connecting the nasal mucosa to structures that maintain the tear film. Stimulation of the anterior ethmoidal nerve with the help of intranasal prongs results in increased tear volume, decreased tear osmolarity, and improved lipid and protein concentrations.<xref ref-type="bibr" rid="article-143508.r51">[51]</xref>&#x000a0;Patients undergo treatment 3 minutes daily for 3 weeks for optimal benefit.&#x000a0;</p>
        <p>
<bold>Targeted Therapy</bold>
</p>
        <p>Targeted treatment may be necessary based on the specific condition associated with MGD, such as plus disease. Common examples of therapy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulsed dose of steroids with ocular surface disease</p>
          </list-item>
          <list-item>
            <p>Steroids for phlyctenular keratitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Epilation or cryotherapy for lash trichiasis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Intralesional steroids or incision and curettage for patients with a chalazion&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lid hygiene, warm compresses, topical antibiotic for anterior blepharitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tea tree oil scrubs for Demodex mite infestation&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143508.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses that mimic meibomian gland disease include diseases that cause eyelid inflammation, conjunctival congestion, or dry eyes. These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Staphylococcal anterior blepharitis:&#x000a0;Characterized by hard eyelash deposits, loss of eyelashes, and distorted lashes or trichiasis, staphylococcal anterior blepharitis is often associated with ulceration or notching of the lid margin. Other related signs include dry eyes, punctate erosions, vascularization, and infiltration of the cornea. Affected patients commonly have atopic dermatitis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seborrheic anterior blepharitis:&#x000a0;This condition, associated with seborrheic dermatitis, is characterized by soft deposits, with or without the loss of distorted eyelashes. Other signs include dry eyes, punctate erosions, vascularization, and corneal infiltration.<xref ref-type="bibr" rid="article-143508.r7">[7]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Demodex blepharitis:&#x000a0;Cylindrical dandruff-like scaling or collarettes around the base of eyelashes characterize this condition, and the mites are visible under high slit lamp magnification.<xref ref-type="bibr" rid="article-143508.r52">[52]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Evaporative dry eyes:&#x000a0;Patients experiencing evaporative dry eyes exhibit irritation, a burning or stinging sensation, fatigue, blurred vision, intolerance to bright light, and discomfort with contact lenses. Clinical examination reveals decreased Schirmer's and TFBUT scores and reduced tear film height. Ocular study findings include corneal punctate epithelial erosions and positive conjunctival and corneal staining. Severe dry eyes may be associated with autoimmune diseases like Sjogren syndrome, rheumatoid arthritis, systemic lupus erythematosus, or diabetes.<xref ref-type="bibr" rid="article-143508.r53">[53]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Conjunctivitis:&#x000a0;Conjunctivitis presents with redness, watering, lid edema, and intolerance to light. Signs include diffuse congestion, follicles, papillae, and matted eyelashes with or without corneal punctate epithelial erosions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cicatricial conjunctivitis:&#x000a0;Cicatrical conjunctivitis is a chronic conjunctivitis with conjunctival fibrosis. Potential causes are Stevens-Johnson syndrome, mucous membrane pemphigoid, and thermal or chemical burns.<xref ref-type="bibr" rid="article-143508.r54">[54]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Contact lens-related keratoconjunctivitis:&#x000a0;This condition presents with red, irritated eyes and is more common in patients who sleep in their contact lenses. When keratitis is significant, visual acuity is affected.<xref ref-type="bibr" rid="article-143508.r55">[55]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Keratitis:&#x000a0;Neurotrophic, filamentary, interstitial, and contact lens-related corneal inflammation forms can compromise the cornea, leading to erosion, ulceration, infiltrates, or scars. Such conditions may result in reduced vision.<xref ref-type="bibr" rid="article-143508.r55">[55]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143508.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis depends&#x000a0;on the disease stage and patient compliance with the prescribed treatment. Daily eyelid hygiene, maintaining humidity in the surroundings, adequate hydration, regular lubrication, frequent blinking, and using sunglasses to shield the eyes from direct wind or sunlight are practical measures to prevent the worsening of MGD and associated evaporative dry eye symptoms. Early-stage MGD can be managed with topical medications alone and may be reversible with good patient compliance.<xref ref-type="bibr" rid="article-143508.r55">[55]</xref></p>
        <p>Interventions such as probing, thermal heating devices, or intense pulsed light therapy may be necessary in advanced stages. Severe dry eyes can result in blurred vision, an inability to wear contact lenses, headaches, corneal keratinization, scarring, or corneal ulcers. Effective treatment and follow-up are crucial to prevent profound, vision-threatening complications in patients with MGD.</p>
      </sec>
      <sec id="article-143508.s12" sec-type="Complications">
        <title>Complications</title>
        <p>MGD&#x000a0;can lead to severe evaporative dry eye disease symptoms when not treated correctly in the early stages. In addition, patients may experience inflammation of the eyelids, further predisposing them to bacterial infection, increased redness of eyelid margins, and unsatisfactory tear film quality. Demodex infestation is another complication in untreated MGD cases.<xref ref-type="bibr" rid="article-143508.r56">[56]</xref>&#x000a0;While treatment of MGD shows that gland regeneration is somewhat possible, the consensus is that meibomian gland loss is only partially reversible, and lack of treatment results in meibomian gland dropout and permanent loss in most cases.<xref ref-type="bibr" rid="article-143508.r57">[57]</xref><xref ref-type="bibr" rid="article-143508.r58">[58]</xref></p>
        <p>In advanced cases, corneal keratinization begins, which can be progressive and challenging to reverse with topical medications. Dilatation of acini leads to atrophy of meibomian gland ducts and the glands themselves over time. Restoring normal function to the glands is difficult.</p>
        <p>Particular caution is necessary for patients with MGD planning on cataract surgery or any other intraocular procedure. Studies show that patients with MGD who undergo cataract surgery are at an increased risk of persistent dry eyes and meibomian gland dropout. These patients are also at risk of penetration of infection from the periocular surfaces when undergoing an intraocular procedure. For this reason, a detailed examination of the eyelids or associated dry eyes is of the utmost importance when examining a patient with a cataract to avoid severe complications like endophthalmitis.<xref ref-type="bibr" rid="article-143508.r59">[59]</xref></p>
        <p>Topical antibiotic ointment with lid hygiene may be sufficient to prevent grave complications like endophthalmitis in patients with MGD. Prolonged topical corticosteroid use may cause elevated intraocular pressures or cataracts. Patients should use alternative regimens and undergo close monitoring to prevent further complications.</p>
      </sec>
      <sec id="article-143508.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>MGD is a chronically recurring disease. Though patients tend to have temporary relief, symptoms usually reappear after some time without ongoing treatment. Thus, patient education is essential to ensure maintenance and regular follow-up. The patient should also understand daily lifestyle modifications, which help prevent disease recurrence. Following any intervention, such as probing, thermal laser treatment, or intense pulse laser therapy, the patient needs topical medications, frequent lid hygiene, and warm compresses to prevent further blocking of the meibomian ducts and promote easy meibum expression.<xref ref-type="bibr" rid="article-143508.r60">[60]</xref></p>
      </sec>
      <sec id="article-143508.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>MGD closely mimics clinical conditions like evaporative dry eyes or anterior seborrheic blepharitis. Patients can present&#x000a0;with&#x000a0;typical symptoms of dry eyes or a different ophthalmic condition like decreased visual acuity secondary to cataracts, refractive error evaluation for contact lenses, or a change of glasses.<xref ref-type="bibr" rid="article-143508.r2">[2]</xref></p>
        <p>Understanding the primary pathology and guiding patients regarding managing MGD based on the presentation stage is essential. Optometrists and general ophthalmologists should manage asymptomatic cases or those presenting early. Patients with advanced disease should be referred to a cornea or ocular surface specialist for detailed evaluation and management.<xref ref-type="bibr" rid="article-143508.r4">[4]</xref></p>
      </sec>
      <sec id="article-143508.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Meibomian gland disease describes a variety of conditions affecting the meibomian glands.&#x000a0;MGD specifically addresses the function of the glands and occurs when the glands in the eyes do not produce enough oil or the oil produced by the glands is too thick. This oil is called meibum, and it protects the layer of tears in the eye to keep it from drying out. The layer of tears in the eyes serves to wash, lubricate, and protect the eye. The eye loses this protection when the meibum is absent or abnormally thick. Patients should be aware of&#x000a0;common symptoms of MGD, such as:</p>
        <list list-type="bullet">
          <list-item>
            <p>A gritty feeling in the eyes</p>
          </list-item>
          <list-item>
            <p>Watery eyes</p>
          </list-item>
          <list-item>
            <p>Sensitivity to light</p>
          </list-item>
          <list-item>
            <p>Poor vision</p>
          </list-item>
          <list-item>
            <p>Dry, flaky skin on the eyelids</p>
          </list-item>
          <list-item>
            <p>Inflamed eyelids</p>
          </list-item>
          <list-item>
            <p>Difficulty wearing contact lenses</p>
          </list-item>
          <list-item>
            <p>Foreign body sensation in the eye</p>
          </list-item>
        </list>
        <p>Aging, hormone changes, infrequent blinking, and a diet low in omega-3 fatty acids or high in omega-6 fatty acids can all cause MGD. MGD occurs when the opening to the meibomian glands becomes clogged.</p>
        <p>The most important part of the treatment is a daily eye care regimen. The key components are applying warm compresses for 10 minutes daily, cleansing the eyes with baby shampoo or lid scrubs, and using&#x000a0;preservative-free eye lubricants and sprays.<xref ref-type="bibr" rid="article-143508.r61">[61]</xref>&#x000a0;Without proper maintenance,&#x000a0;MGD will worsen, and the number of meibomian glands will eventually decrease. As the disease progresses, symptoms worsen, and prescription medication or surgical intervention may be necessary. If left untreated, permanent damage to the eye and vision loss may occur.</p>
      </sec>
      <sec id="article-143508.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key points to keep in mind about MGD include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>MGD is a chronic, diffuse abnormality of the meibomian glands characterized by terminal duct obstruction and qualitative or quantitative glandular secretion changes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The classical findings of eyelid inflammation, meibomian glands expressibility, conjunctival or corneal staining, and tear film height provide essential clues regarding management.<xref ref-type="bibr" rid="article-143508.r62">[62]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MGD involves alterations in the function of the meibomian glands, leading to abnormalities in meibum secretion. This can result in alterations in tear film composition and compromise ocular surface health.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnostic methods used for MGD include&#x000a0;slit lamp examination, meibography to visualize gland morphology and dropout, tear film breakup time (TFBUT), tear osmolarity measurement, and conjunctival and corneal staining.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Management options for MGD include conservative measures such as warm compresses, eyelid hygiene, artificial tears, omega-3 fatty acid supplementation, and lifestyle modifications. Advanced cases may require procedures such as intraductal probing, mechanical expression of meibomian glands, and prescription medications like topical antibiotics, steroids, or immunomodulators.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Potential complications of untreated or poorly managed MGD include chronic dry eye symptoms, corneal complications such as keratitis or ulceration, and vision impairment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MGD may be associated with other systemic conditions such as rosacea, seborrheic dermatitis, and autoimmune disorders.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients not improving with conservative forms of treatment should be referred to an ocular surface specialist for detailed evaluation.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143508.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MGD&#x000a0;is a prevalent yet often overlooked disorder, leading to underdiagnosis and undertreatment. Many patients are asymptomatic in the early stages, complicating prompt diagnosis and intervention. Early&#x000a0;identification&#x000a0;and treatment prolong the asymptomatic phase and prevent meibomian gland dropout and irreversible ocular damage, including vision loss.</p>
        <p>Caring for patients with MGD requires a multidisciplinary approach. Given the overlap of symptoms with common, more benign ocular conditions, healthcare professionals must possess the necessary clinical skills and expertise to diagnose, evaluate, and treat this condition. Clinicians require expertise in recognizing asymptomatic and symptomatic MGD and understanding the nuances of diagnostic techniques such as slit-lamp examination, meibography, tear meniscus height, and the measurement of tear osmolarity and TFBT.</p>
        <p>Patient education regarding the importance of a daily eyecare regimen is necessary to prevent the progression of the disease and improve overall symptoms. Effective interprofessional communication is essential to ensure effective information exchange and collaborative decision-making among the team members. Updated medication lists allow prescribers to avoid medications that interfere with meiobiam gland function and tear production. Comprehensive knowledge of MGD heightens the awareness of clinicians who evaluate patients for ocular conditions, promoting the consideration of MGD more frequently and allowing for timely diagnosis and referral to the appropriate specialist when necessary. This coordination reduces delays in diagnosis and improves patient outcomes and overall quality of care.</p>
      </sec>
      <sec id="article-143508.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143508&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143508">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/meibomian-gland-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=143508">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143508/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143508">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-143508.s19">
        <fig id="article-143508.image.f1" position="float" orientation="portrait">
          <caption>
            <p>MGD-Induced Dry Eye Sequelae. A digital slit-lamp image of the patient&#x000a0;reveals&#x000a0;upper eyelid matted lashes, seborrheic blepharitis in lower eyelashes, and upper lid margin with blocked meibomian glands&#x000a0;displaying a sago grain appearance. Additionally, corneal superficial vascularization&#x000a0;and a&#x000a0;central nebular corneal opacity suggestive of MGD-induced dry eye sequelae in the patient are observed. Contributed by Dr. Kirandeep Kaur, MBBS, DNB, FPOS, FICO, MRCS Ed, MNAMS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1211879_20170203_234545_DC4Image_L_004" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-143508.s20">
        <fig id="article-143508.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Lower Eyelid Frothing. A digital slit-lamp image of the patient depicting frothing on the lower eyelid margin suggests meibomian gland disease. Contributed by Dr. Kirandeep Kaur, MBBS, DNB, FPOS, FICO, MRCS Ed, MNAMSd</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mn_20171113_155252_DC4Image_L_000" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-143508.s21">
        <fig id="article-143508.image.f3" position="float" orientation="portrait">
          <caption>
            <p>MGD on Meibography. A meibography image distinguishes MGD. Contributed by Thomas Stokkermans OD MS PhD FAAO</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Meibography__image" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-143508.s22">
        <title>References</title>
        <ref id="article-143508.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Shimazaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benitez-del-Castillo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>McCulley</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Den</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Foulks</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>1930</fpage>
            <page-range>1930-7</page-range>
            <pub-id pub-id-type="pmid">21450914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milner</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Beckman</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Luchs</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>QB</given-names>
              </name>
              <name>
                <surname>Awdeh</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Berdahl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Buznego</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Majmudar</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Rajpal</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Raviv</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rowen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shamie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stonecipher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tauber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trattler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Yeu</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>27 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>3</fpage>
            <page-range>3-47</page-range>
            <pub-id pub-id-type="pmid">28099212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knop</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Knop</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Obata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>1938</fpage>
            <page-range>1938-78</page-range>
            <pub-id pub-id-type="pmid">21450915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomlinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Korb</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paugh</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dogru</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>2006</fpage>
            <page-range>2006-49</page-range>
            <pub-id pub-id-type="pmid">21450918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chhadva</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goldhardt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Galor</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease.</article-title>
            <source>Ophthalmology</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>124</volume>
            <issue>11S</issue>
            <fpage>S20</fpage>
            <page-range>S20-S26</page-range>
            <pub-id pub-id-type="pmid">29055358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geerling</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aragona</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rolando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boboridis</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Ben&#x000ed;tez-Del-Castillo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Akova</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Merayo-Lloves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Labetoulle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinhoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messmer</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting.</article-title>
            <source>Ocul Surf</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-192</page-range>
            <pub-id pub-id-type="pmid">28132878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Putnam</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of blepharitis: an optometrist's perspective.</article-title>
            <source>Clin Optom (Auckl)</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>71</fpage>
            <page-range>71-78</page-range>
            <pub-id pub-id-type="pmid">30214351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaumberg</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Papas</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Uchino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>1994</fpage>
            <page-range>1994-2005</page-range>
            <pub-id pub-id-type="pmid">21450917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurlevik</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kemeriz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yasar</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The effect of isotretinoin on meibomian glands in eyes: a pilot study.</article-title>
            <source>Int Ophthalmol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>7</issue>
            <fpage>2071</fpage>
            <page-range>2071-2078</page-range>
            <pub-id pub-id-type="pmid">34978652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>XH</given-names>
              </name>
            </person-group>
            <article-title>The association of demodex infestation with pediatric chalazia.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>16</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>124</fpage>
            <pub-id pub-id-type="pmid">35291979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>The varied influence of ocular Demodex infestation on dry eye disease and meibomian gland dysfunction across different age groups.</article-title>
            <source>Sci Rep</source>
            <year>2023</year>
            <month>Sep</month>
            <day>28</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>16324</fpage>
            <pub-id pub-id-type="pmid">37770583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Demodex infection rate and risk factors in patients with meibomian gland dysfunction.</article-title>
            <source>Int Ophthalmol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>877</fpage>
            <page-range>877-884</page-range>
            <pub-id pub-id-type="pmid">36109404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassanzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varmaghani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zarei-Ghanavati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heravian Shandiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Azimi Khorasani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Global Prevalence of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2021</year>
            <month>Jan</month>
            <day>02</day>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-75</page-range>
            <pub-id pub-id-type="pmid">32589483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Inflamed Obstructive Meibomian Gland Dysfunction Causes Ocular Surface Inflammation.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>59</volume>
            <issue>14</issue>
            <fpage>DES94</fpage>
            <page-range>DES94-DES101</page-range>
            <pub-id pub-id-type="pmid">30481812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messmer</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology, diagnosis, and treatment of dry eye disease.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2015</year>
            <month>Jan</month>
            <day>30</day>
            <volume>112</volume>
            <issue>5</issue>
            <fpage>71</fpage>
            <page-range>71-81; quiz 82</page-range>
            <pub-id pub-id-type="pmid">25686388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutgesell</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Hood</surname>
                <given-names>CI</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of meibomian gland dysfunction.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1982</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-7</page-range>
            <pub-id pub-id-type="pmid">7124880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obata</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Anatomy and histopathology of human meibomian gland.</article-title>
            <source>Cornea</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>7 Suppl</issue>
            <fpage>S70</fpage>
            <page-range>S70-4</page-range>
            <pub-id pub-id-type="pmid">12484702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Efron</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Grading scales for contact lens complications.</article-title>
            <source>Ophthalmic Physiol Opt</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-6</page-range>
            <pub-id pub-id-type="pmid">9692040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paugh</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Senchyna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meadows</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Development of a Meibomian Gland Dysfunction-Specific Symptom Questionnaire.</article-title>
            <source>Eye Contact Lens</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-14</page-range>
            <pub-id pub-id-type="pmid">27466720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okumura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Inomata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujio</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Midorikawa-Inomata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Review of Dry Eye Questionnaires: Measuring Patient-Reported Outcomes and Health-Related Quality of Life.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2020</year>
            <month>Aug</month>
            <day>05</day>
            <volume>10</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">32764273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Whang</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Relationship between eyelid margin irregularity and meibomian gland dropout.</article-title>
            <source>Ocul Surf</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>19</volume>
            <fpage>31</fpage>
            <page-range>31-37</page-range>
            <pub-id pub-id-type="pmid">33246034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rabut</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Augstburger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Labb&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Role of Meibography in the Diagnosis of Meibomian Gland Dysfunction in Ocular Surface Diseases.</article-title>
            <source>Transl Vis Sci Technol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">31737430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wise</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Meibography: A review of techniques and technologies.</article-title>
            <source>Saudi J Ophthalmol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">23961019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Ocular surface analysis: A comparison between the LipiView<sup>&#x000ae;</sup> II and IDRA<sup>&#x000ae;</sup>.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>2300</fpage>
            <page-range>2300-2306</page-range>
            <pub-id pub-id-type="pmid">33267698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawashima</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Proposed Algorithm for Management of Meibomian Gland Dysfunction Based on Noninvasive Meibography.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Dec</month>
            <day>27</day>
            <volume>10</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33375436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabeti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kheirkhah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dana</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of meibomian gland dysfunction: a review.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-217</page-range>
            <pub-id pub-id-type="pmid">31494111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yokoi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Tiffany</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Maruyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Komuro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Relationship between tear volume and tear meniscus curvature.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>122</volume>
            <issue>9</issue>
            <fpage>1265</fpage>
            <page-range>1265-9</page-range>
            <pub-id pub-id-type="pmid">15364704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Comparison of meibomian gland dropout using two infrared imaging devices.</article-title>
            <source>Cont Lens Anterior Eye</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-317</page-range>
            <pub-id pub-id-type="pmid">30413376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pistilli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bunya</surname>
                <given-names>VY</given-names>
              </name>
              <name>
                <surname>Massaro-Giordano</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kadakia</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Asbell</surname>
                <given-names>PA</given-names>
              </name>
              <collab>Dry Eye Assessment and Management (DREAM) Study Research Group</collab>
            </person-group>
            <article-title>Grading and baseline characteristics of meibomian glands in meibography images and their clinical associations in the Dry Eye Assessment and Management (DREAM) study.</article-title>
            <source>Ocul Surf</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>491</fpage>
            <page-range>491-501</page-range>
            <pub-id pub-id-type="pmid">31022469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pucker</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jones-Jordan</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sickenberger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>L</given-names>
              </name>
              <collab>Contact Lens Assessment of Symptomatic Subjects (CLASS) Study Group</collab>
            </person-group>
            <article-title>Clinical factors associated with contact lens dropout.</article-title>
            <source>Cont Lens Anterior Eye</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>318</fpage>
            <page-range>318-324</page-range>
            <pub-id pub-id-type="pmid">30538060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merayo-Lloves</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Management Strategies for Evaporative Dry Eye Disease and Future Perspective.</article-title>
            <source>Curr Eye Res</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>813</fpage>
            <page-range>813-823</page-range>
            <pub-id pub-id-type="pmid">35521685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swiderska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Blackie</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Maldonado-Codina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Latest developments in meibography: A review.</article-title>
            <source>Ocul Surf</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>25</volume>
            <fpage>119</fpage>
            <page-range>119-128</page-range>
            <pub-id pub-id-type="pmid">35724917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nichols</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Foulks</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Glasgow</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dogru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsubota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lemp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The international workshop on meibomian gland dysfunction: executive summary.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2011</year>
            <month>Mar</month>
            <day>30</day>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>1922</fpage>
            <page-range>1922-9</page-range>
            <pub-id pub-id-type="pmid">21450913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kocami&#x0015f;</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Temel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>A&#x0015f;ikgarip</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>&#x000d6;rnek</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Electronic Device Screen Time and Meibomian Gland Morphology in Children.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2021</year>
            <season>Oct-Dec</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>531</fpage>
            <page-range>531-537</page-range>
            <pub-id pub-id-type="pmid">34840674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macsai</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis).</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>2008</year>
            <volume>106</volume>
            <fpage>336</fpage>
            <page-range>336-56</page-range>
            <pub-id pub-id-type="pmid">19277245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ole&#x000f1;ik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahillo-Fern&#x000e1;ndez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Alejandre-Alba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Sanz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Luxan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Quintana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez de Carneros Llorente</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Sandoval</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez-Alfaro</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>831</fpage>
            <page-range>831-6</page-range>
            <pub-id pub-id-type="pmid">24812490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garrigue</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Amrane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Holopainen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Relevance of Lipid-Based Products in the Management of Dry Eye Disease.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>647</fpage>
            <page-range>647-661</page-range>
            <pub-id pub-id-type="pmid">28956698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction.</article-title>
            <source>Int J Ophthalmol</source>
            <year>2018</year>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>593</fpage>
            <page-range>593-600</page-range>
            <pub-id pub-id-type="pmid">29675376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qiao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Emerging treatment options for meibomian gland dysfunction.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2013</year>
            <volume>7</volume>
            <fpage>1797</fpage>
            <page-range>1797-803</page-range>
            <pub-id pub-id-type="pmid">24043929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pflugfelder</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nicotinic acetylcholine receptor stimulation: A new approach for stimulating tear secretion in dry eye disease.</article-title>
            <source>Ocul Surf</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>25</volume>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">35550851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maskin</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction.</article-title>
            <source>Cornea</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1145</fpage>
            <page-range>1145-52</page-range>
            <pub-id pub-id-type="pmid">20622668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moschowits</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vehof</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Utheim</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2021</year>
            <season>Jul-Aug</season>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>612</fpage>
            <page-range>612-622</page-range>
            <pub-id pub-id-type="pmid">33352147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Sutula</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Dynamic Intraductal Meibomian Probing: A Modified Approach to the Treatment of Obstructive Meibomian Gland Dysfunction.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2017</year>
            <season>Jul/Aug</season>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-309</page-range>
            <pub-id pub-id-type="pmid">28221295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lane</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>DuBiner</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ernest</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Greiner</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Hardten</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lemp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Silbert</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Blackie</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bedi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A new system, the LipiFlow, for the treatment of meibomian gland dysfunction.</article-title>
            <source>Cornea</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>396</fpage>
            <page-range>396-404</page-range>
            <pub-id pub-id-type="pmid">22222996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greiner</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Long-Term (3 Year) Effects of a Single Thermal Pulsation System Treatment on Meibomian Gland Function and Dry Eye Symptoms.</article-title>
            <source>Eye Contact Lens</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-107</page-range>
            <pub-id pub-id-type="pmid">26222095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hayajneh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borrelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schrader</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Geerling</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy.</article-title>
            <source>Cornea</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1265</fpage>
            <page-range>1265-70</page-range>
            <pub-id pub-id-type="pmid">25321941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wesley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bickle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Downing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heinrich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kading</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kannarr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ludwick</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tauber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manoj</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study.</article-title>
            <source>Optom Vis Sci</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <page-range>323-332</page-range>
            <pub-id pub-id-type="pmid">35383732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jie</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>261</fpage>
            <page-range>261-270</page-range>
            <pub-id pub-id-type="pmid">34822140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Current trends in intense pulsed light.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>45</fpage>
            <page-range>45-53</page-range>
            <pub-id pub-id-type="pmid">22768357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e4;umler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vural</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Landthaler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muzzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shafirstein</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The effects of intense pulsed light (IPL) on blood vessels investigated by mathematical modeling.</article-title>
            <source>Lasers Surg Med</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-9</page-range>
            <pub-id pub-id-type="pmid">17066482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brinton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kossler</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Loudin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ta</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Palanker</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>2341</fpage>
            <page-range>2341-2348</page-range>
            <pub-id pub-id-type="pmid">28431436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhandari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Blepharitis: always remember demodex.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2014</year>
            <season>Oct-Dec</season>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-20</page-range>
            <pub-id pub-id-type="pmid">25371637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Moutsopoulos</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Clinical manifestations and early diagnosis of Sj&#x000f6;gren syndrome.</article-title>
            <source>Arch Intern Med</source>
            <year>2004</year>
            <month>Jun</month>
            <day>28</day>
            <volume>164</volume>
            <issue>12</issue>
            <fpage>1275</fpage>
            <page-range>1275-84</page-range>
            <pub-id pub-id-type="pmid">15226160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vazirani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donthineni</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sane</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mahuvakar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shanbhag</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Chronic cicatrizing conjunctivitis: A review of the differential diagnosis and an algorithmic approach to management.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>11</issue>
            <fpage>2349</fpage>
            <page-range>2349-2355</page-range>
            <pub-id pub-id-type="pmid">33120615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cope</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Konne</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Dhaliwal</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinemann</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Corneal Infections Associated with Sleeping in Contact Lenses - Six Cases, United States, 2016-2018.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>17</day>
            <volume>67</volume>
            <issue>32</issue>
            <fpage>877</fpage>
            <page-range>877-881</page-range>
            <pub-id pub-id-type="pmid">30114003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The association between <italic>demodex</italic> infestation and ocular surface manifestations in meibomian gland dysfunction.</article-title>
            <source>Int J Ophthalmol</source>
            <year>2018</year>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>589</fpage>
            <page-range>589-592</page-range>
            <pub-id pub-id-type="pmid">29675375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suehiro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haraguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tokoro</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Topical diquafosol for patients with obstructive meibomian gland dysfunction.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>725</fpage>
            <page-range>725-9</page-range>
            <pub-id pub-id-type="pmid">23584719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maskin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Testa</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-68</page-range>
            <pub-id pub-id-type="pmid">28592418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pathogens in the Meibomian gland and conjunctival sac: microbiome of normal subjects and patients with Meibomian gland dysfunction.</article-title>
            <source>Infect Drug Resist</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1729</fpage>
            <page-range>1729-1740</page-range>
            <pub-id pub-id-type="pmid">30349330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Non-pharmaceutical treatment options for meibomian gland dysfunction.</article-title>
            <source>Clin Exp Optom</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>742</fpage>
            <page-range>742-755</page-range>
            <pub-id pub-id-type="pmid">31943385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Reversibility of Gland Dropout and Significance of Eyelid Hygiene Treatment in Meibomian Gland Dysfunction.</article-title>
            <source>Cornea</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-337</page-range>
            <pub-id pub-id-type="pmid">27755193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143508.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mizoguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwanishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shirai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sumioka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kokado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jester</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Saika</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ocular surface inflammation impairs structure and function of meibomian gland.</article-title>
            <source>Exp Eye Res</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>163</volume>
            <fpage>78</fpage>
            <page-range>78-84</page-range>
            <pub-id pub-id-type="pmid">28950941</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
